Dr. Arun Menawat is Chairman and CEO of Profound Medical Inc. (NASDAQ:PROF, TSX:PRN), a commercial stage medical technology company that markets real-time MRI-guided thermal ultrasound systems for incision-free ablation of abnormal or cancerous tissue. Profound’s key product is the TULSA-PRO therapeutic system, designed for precise and customizable ablation of diseased prostate tissue. Prior to joining Profound, Arun served as the Chairman and CEO of Novadaq Technologies Inc. for 13 years, guiding the company from a start-up to one of the fastest-growing, NASDAQ listed medical technology companies in North America, with a market cap of over $ 1 Billion USD. During his tenure, Novadaq pioneered the field of fluorescence imaging and built a powerful new ecosystem that provides clinically relevant imaging solutions to improve outcomes at multiple points throughout the patient care continuum. Arun previously served as President of Cedara Software Corp., a company that developed the industry’s first medical imaging software platform. Under his leadership, Cedara achieved profitability and was ultimately acquired. Today, the company’s imaging platform and its big data collection are part of IBM’s Watson program. Arun also serves as a member of the board of directors or advisor to growth oriented life science companies. Earlier in his career, Arun held executive positions at Tenneco Inc. and Hercules Inc. in the areas of business development, technology development and mergers/acquisitions. He obtained a Ph.D. in Chemical Engineering from the University of Maryland, and an Executive MBA from the J.L. Kellogg School of Management, Northwestern University. In 2014, he was named the EY Ontario Entrepreneur of the Year in the health sciences category. Dr. Arun Menawat is Chairman and CEO of Profound Medical Inc. (NASDAQ:PROF, TSX:PRN), a commercial stage medical technology company that markets real-time MRI-guided thermal ultrasound systems for incision-free ablation of abnormal or cancerous tissue. Profound’s key product is the TULSA-PRO therapeutic system, designed for precise and customizable ablation of diseased prostate tissue. Prior to joining Profound, Arun served as the Chairman and CEO of Novadaq Technologies Inc. for 13 years, guiding the company from a start-up to one of the fastest-growing, NASDAQ listed medical technology companies in North America, with a market cap of over $ 1 Billion USD. During his tenure, Novadaq pioneered the field of fluorescence imaging and built a powerful new ecosystem that provides clinically relevant imaging solutions to improve outcomes at multiple points throughout the patient care continuum. Arun previously served as President of Cedara Software Corp., a company that developed the industry’s first medical imaging software platform. Under his leadership, Cedara achieved profitability and was ultimately acquired. Today, the company’s imaging platform and its big data collection are part of IBM’s Watson program. Arun also serves as a member of the board of directors or advisor to growth oriented life science companies. Earlier in his career, Arun held executive positions at Tenneco Inc. and Hercules Inc. in the areas of business development, technology development and mergers/acquisitions. He obtained a Ph.D. in Chemical Engineering from the University of Maryland, and an Executive MBA from the J.L. Kellogg School of Management, Northwestern University. In 2014, he was named the EY Ontario Entrepreneur of the Year in the health sciences category.

• 

  Advisor in Amplitude Ventures

  We stand proudly on a foundation of deep experience and a demonstrable body of success creating, building, and growing break-out companies.|

• 

  Chairman of the Board in Profound Medical

  Incision-Free Ablative Intervention, with Vision

• 

  Chief Executive Officer (CEO) in Profound Medical

  Incision-Free Ablative Intervention, with Vision